Compare Teucrium Corn Fund (CORN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Corn Fund vs Smith & Nephew plc — how do they compare? Teucrium Corn Fund trades at $17.55, while Smith & Nephew plc trades at $30.06 (market cap $12.40B). The key difference: Smith & Nephew plc pays a 2.62% dividend while Teucrium Corn Fund pays none, and Teucrium Corn Fund is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| CORN | SNN | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $19.12 | $38.70 |
52-Week Low | $16.46 | $28.73 |
Market Cap | — | $12.40B |
Enterprise Value | — | $15.17B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORN stock trades at $17.55 with a slight 0.4% daily gain, showing bullish technical momentum with strong moving average support. The company's financial ratios remain undisclosed in current data, limiting fundamental visibility. Recent partnership news with Hormel Foods for CORN NUTS brand licensing provides potential growth catalyst, while technical indicators suggest continued upward pressure with key resistance at $18.
Outlook remains cautiously optimistic given bullish technical signals and brand expansion opportunities, though limited financial transparency presents valuation challenges. Key risks include commodity price volatility and competitive pressures in the snack food sector. Investors should monitor upcoming earnings for fundamental clarity while technical momentum supports near-term upside potential.
SNN trades at $31.08, up 1.24% with a bullish technical signal. The company shows improving fundamentals with 2024 revenue of $5.81B and net income of $412M, while recent earnings beat expectations. Strong cash flow generation and new product launches in robotics and wound care support growth. Analyst consensus is mixed with 27% buy ratings but majority holds.
Outlook remains positive with projected revenue growth and margin expansion, though recent earnings misses and elevated valuation metrics pose risks. The stock's technical strength and fundamental recovery present opportunity, but investor caution is warranted given mixed analyst sentiment and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
